Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Ironwood and Forest Laboratories Submit Linaclotide to FDA

By Drug Discovery Trends Editor | August 10, 2011

Ironwood Pharmaceuticals Inc. and Forest Laboratories Inc. have submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for linaclotide, a guanylate cyclase type?C (GC?C) agonist, for the treatment of irritable bowel syndrome with constipation (IBS?C) and chronic constipation (CC).

Linaclotide, an investigational drug, is an agonist of the guanylate cyclase type?C (GC?C) receptor located on the luminal surface of the intestine. In preclinical models, linaclotide reduced visceral hypersensitivity, increased fluid secretion, and accelerated intestinal transit.

The submission includes efficacy and safety data from a Phase 3 program comprising four double?blind placebo?controlled trials and two open?label long term safety studies. More than 2,800 patients received a once?daily dose of either linaclotide or placebo across the four placebo?controlled clinical trials: two trials in patients with IBS?C and two trials in patients with CC.

In the trials, statistically significant improvements in abdominal and bowel symptoms were achieved for linaclotide?treated patients versus placebo?treated patients for all primary and
secondary endpoints. Safety data collected across the four placebo?controlled Phase 3 clinical trials demonstrated that diarrhea was the most commonly reported adverse event and led to study discontinuation in 4% to 5% of linaclotide?treated patients compared to fewer than 1% of patients receiving placebo.

Additionally, over 3,200 patients have enrolled in ongoing open?label safety studies and more than 1,100 of those patients have received linaclotide for at least 12 months.

Release Date: August 9, 2011
Source: Ironwood Pharmaceuticals, Inc. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50